Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avecho Biotechnology Ord Shs V.AVE


Primary Symbol: AVEFF

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.


OTCPK:AVEFF - Post by User

Comment by MuskokaJoe68on May 16, 2017 7:30pm
63 Views
Post# 26252442

RE:RE:Q1: Record Revenue up 241% with 6.5M Improvement in EBITDA…

RE:RE:Q1: Record Revenue up 241% with 6.5M Improvement in EBITDA…All in all. Seems like a 1.00 stock price is a great start. Great point on revenue mix, couldn't agree more with 90%of revenues from US with a focus around Texas no spring break low in business in Q2 like all the other energy services companies. Aveda should easily out preform what already was a stellar Q1 in Q2 and not many companies in this industry can say that.  Trading at 2-3x Ebitda valuation is  bananas! If the stock price finally gets over that 0.60 level look out this thing will fly, there will be no more sellers left.
Bullboard Posts